复发卵巢癌腹腔热灌注化疗(CHIPOR):一项随机、开放标签、3期试验
CHIPOR试验在法国、比利时、西班牙和加拿大31个中心纳入415例首次复发的上皮性卵巢癌患者,随机分为腹腔热灌注化疗(HIPEC)组207例和无HIPEC组208例。中位随访6.2年,HIPEC组中位总生存54.3个月 vs 无HIPEC组45.8个月(分层HR 0.73,95%CI 0.56-0.96;p=0.024)。HIPEC组3级及以上不良事件发生率49% vs 27%。
要点
- 首次复发上皮性卵巢癌在铂类化疗应答后行肿瘤细胞减灭术加HIPEC,中位总生存54.3个月 vs 45.8个月(HR 0.73)。
- HIPEC组术后60天内3级及以上不良事件102/207例(49%),无HIPEC组56/208例(27%)。
- 最常见的3级及以上不良事件为贫血、肝毒性、电解质紊乱和肾功能衰竭。
核心结论
- 在首次复发上皮性卵巢癌患者中,对铂类化疗应答后行肿瘤细胞减灭术时加用HIPEC可显著改善总生存。
- 作者认为,在专科中心治疗适合完全肿瘤细胞减灭术的晚期首次复发高级别浆液性或高级别子宫内膜样卵巢癌患者时,应考虑以铂类为基础的HIPEC以延长总生存。
研究设计与样本
- 多中心、开放标签、随机、3期CHIPOR试验,在法国、比利时、西班牙和加拿大31个中心开展。
- 纳入完成铂类化疗至少6个月后首次复发的上皮性卵巢癌患者,年龄18岁及以上,WHO体能状态评分小于2。
- 经6个周期铂类化疗(可选贝伐珠单抗)后适合完全肿瘤细胞减灭术的患者,在手术中按1:1比例中央随机分配接受或不接受HIPEC,按中心、肿瘤细胞减灭 completeness 评分、无铂间期及后期计划的多聚ADP核糖聚合酶抑制剂使用分层。
- HIPEC方案为顺铂75 mg/m2溶于2 L/m2血清中,41±1°C,持续60分钟。
- 主要终点为总生存,按意向性治疗原则在所有随机分配患者中分析;共415例女性患者随机分配(HIPEC组207例,无HIPEC组208例)。
主要发现
- 2011年5月11日至2021年5月14日共随机分配415例女性患者(HIPEC组207例,无HIPEC组208例)。
- 主要分析时中位随访6.2年(IQR 4.1-8.1),268例(65%)患者死亡(HIPEC组126/207例[61%];无HIPEC组142/208例[68%])。
- HIPEC组总生存显著改善(分层风险比0.73,95%CI 0.56-0.96;p=0.024)。
- HIPEC组中位总生存54.3个月(95%CI 41.9-61.7)vs 无HIPEC组45.8个月(95%CI 38.9-54.2)。
- 术后60天内3级及以上不良事件:HIPEC组102/207例(49%)vs 无HIPEC组56/208例(27%);最常见为贫血(47例[23%] vs 30例[14%])、肝毒性(23例[11%] vs 18例[9%])、电解质紊乱(28例[14%] vs 2例[1%])和肾功能衰竭(20例[10%] vs 3例[1%])。
关键数值与推荐
- HIPEC组中位总生存54.3个月(95%CI 41.9-61.7)vs 无HIPEC组45.8个月(95%CI 38.9-54.2),分层风险比0.73(95%CI 0.56-0.96;p=0.024)。
- HIPEC方案:顺铂75 mg/m2溶于2 L/m2血清中,41±1°C,持续60分钟。
- 术后60天内3级及以上不良事件发生率:HIPEC组49%(102/207)vs 无HIPEC组27%(56/208)。
临床怎么用
- 作者认为,在专科中心治疗适合完全肿瘤细胞减灭术的晚期首次复发高级别浆液性或高级别子宫内膜样卵巢癌患者时,应考虑以铂类为基础的HIPEC以延长总生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hyperthermic intraperitoneal chemotherapy (HIPEC) at interval cytoreductive surgery for ovarian cancer improves overall survival but its role in recurrent disease is uncertain. We aimed to compare outcomes in patients treated with or without HIPEC during surgery for recurrent ovarian cancer. METHODS: The multicentre, open-label, randomised, phase 3 CHIPOR trial was conducted at 31 sites in France, Belgium, Spain, and Canada, and enrolled patients with first relapse of epithelial ovarian cancer at least 6 months after completing platinum-based chemotherapy. Eligible patients were aged 18 years or older with WHO performance status of less than 2. After six cycles of platinum-based chemotherapy (and optional bevacizumab), patients amenable to complete cytoreductive surgery were randomly assigned centrally in a 1:1 ratio, using a web-based system and a minimisation procedure, during surgery to receive HIPEC (cisplatin 75 mg/m2 in 2 L/m2 of serum at 41±1°C for 60 min) or not, stratified by centre, completeness of cytoreduction score, platinum-free interval, and latterly, planned poly(ADP-ribose) polymerase inhibitor use. The primary endpoint was overall survival, analysed on an intention-to-treat basis in all randomly assigned patients. This ongoing trial is registered with ClinicalTrials.gov, NCT01376752. FINDINGS: Between May 11, 2011, and May 14, 2021, 415 female patients were randomly assigned (207 HIPEC, 208 no HIPEC). At the primary analysis (median follow-up 6·2 years, IQR 4·1-8·1), 268 (65%) patients had died (126 [61%] of 207 in the HIPEC group; 142 [68%] of 208 in the no-HIPEC group). Overall survival was significantly improved with HIPEC (stratified hazard ratio 0·73, 95% CI 0·56-0·96; p=0·024). Median overall survival was 54·3 months (95% CI 41·9-61·7) with HIPEC versus 45·8 months (38·9-54·2) without. Grade 3 or worse adverse events within 60 days after surgery occurred in 102 (49%) of 207 patients receiving HIPEC versus 56 (27%) of 208 receiving no HIPEC, the most common being anaemia (47 [23%] vs 30 [14%]), hepatotoxicity (23 [11%] vs 18 [9%]), electrolyte disturbance (28 [14%] vs two [1%]), and renal failure (20 [10%] vs three [1%]). There were three deaths within 60 days of surgery, all in the no-HIPEC group. INTERPRETATION: Adding HIPEC to cytoreductive surgery after response to platinum-based chemotherapy at first epithelial ovarian cancer recurrence significantly improved overall survival. When treating patients with late first relapse of high-grade serous or high-grade endometrioid ovarian cancer amenable to complete cytoreductive surgery at specialist centres, platinum-based HIPEC should be considered to extend overall survival. FUNDING: French National Cancer Institute and French League Against Cancer.
引用
- Classe JM, Meeus P, Hudry D, et al. Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2024. PMID: 39549720. doi:10.1016/S1470-2045(24)00531-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。